This message was sent to ##Email##
|
| July 8, 2020 |
| |  | | |
|
| |
TIME
Liz Satterfield has a ritual for every time she returns home after leaving the house. Diagnosed with metastatic breast cancer in 2016, the Kirkland, Washington resident recently learned that the cancer that had spread to her brain in 2018 was still growing. Throughout the pandemic, she’s had to visit the hospital at least once every three weeks, often more frequently, for treatments to control her disease.
READ MORE
ASCT
For over forty years, the ASCT has been committed to its role as the collective voice for cytotechnologists!
The field is constantly evolving, and the cytotechnologist's role is expanding at a more rapid pace than ever. We are integral members of the diagnostic team, and as such, it is important to bring our needs and ideas to the forefront of an ever-changing work environment. The ASCT remains focused on providing its members with significant resources to help you stay current on critical issues involving workload, proficiency testing, licensure, continuing education, and the workforce.
Your support as an active member is essential for the ASCT to remain the only national society that solely represents cytotechnologists. Your membership and involvement directly impact our ability to serve your personal needs, as well as the needs of our profession.
We invite you to renew your membership today!
To Renew Online
Visit to www.asct.com and log into your personal account by clicking Sign In at the top of the web page and entering your user name and password. Next, click the My Membership tab.
If you forgot your user name and password, contact info@asct.com.
 |
|
The F-50 Non-Gyn Slide Processor has a liquid-based cytology system that features more cells per slide, and doesn’t need duplicate preps. The dual filtration disposable filters remove non-diagnostic material to optimize cell presentation. Cells of interest are transferred to the slide in a homogenous thin-layer cell deposit. Throughput: 50 samples/hr.
|
|
| Date |
Event |
Location |
More information |
Available for 6 months after subscribing |
Quality Assessment Center (QAC) Cell Blocks Basics Workbench
|
Your PC |
Details |
Available for 6 months after subscribing |
Quality Assessment Center (QAC)
Document Control for Cytopathology Workbench
|
Your PC |
Details |
Available for 6 months after subscribing |
Quality Assessment Center (QAC)
The LEAN Cytopathology Laboratory Workbench
|
Your PC |
Details |
Healio
An educational comic book about HPV and HPV vaccine improved college students’ attitudes about completing the vaccination process and their intention to do so within one year. The findings were presented during the 2020 Virtual Annual Conference on Vaccinology Research sponsored by the National Foundation for Infectious Diseases.
READ MORE
UCLA Newsroom
A UCLA-led study has found that in 2 of 3 states and jurisdictions with policies that require students entering school to receive the human papillomavirus vaccine, vaccination rates among 13-to-17-year-olds were significantly higher than in surrounding states without such policies.
In Rhode Island, the vaccination rate among adolescents was 91%, compared with an average of 78% in neighboring non-policy states. In the District of Columbia, the rate was 89%, compared with 72% for nearby non-policy states. Virginia, which is in the same region as the district, was the one state with a vaccination policy that showed no difference from surrounding states. (68% vs. 72%).
READ MORE
|
|
|
|
|
| |
Dermatology Times
Novel and emerging nanotechnology approaches used in the treatment of skin cancer are generating interest as they enable the efficient delivery of drugs and other bioactive molecules to target tissues with low toxic effects. A recent study1 examined current investigations of nanoparticle and nanosystems and highlighted the therapeutic benefit and potentially larger role in the treatment of skin cancer.
Depending on disease stage, melanoma and nonmelanoma skin cancers can be treated in a variety of ways. However, the limitations of some treatment modalities have led research to explore new delivery systems and approaches to help improve clinical outcomes.
READ MORE
FDA
Today, the U.S. Food and Drug Administration approved Phesgo — a combination of pertuzumab, trastuzumab and hyaluronidase – zzxf — for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adult patients with early HER2-positive breast cancer. Patients should be selected based on an FDA-approved companion diagnostic test.
READ MORE
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
